Inseego Wavemaker™ PRO 5G Indoor Router Approved for Enterprise and SMB Customers Worldwide
9.2.2021 17:00:00 EET | Business Wire | Press release
Inseego Corp. (Nasdaq: INSG), a leader in 5G and intelligent IoT device-to-cloud solutions, today announced that its new Wavemaker PRO 5G indoor router has been certified for use in Europe, North America* and Australia, with additional regulatory certifications pending for other international markets. Designed specifically for enterprise customers, this router combines high-performance, multi-carrier 5G and Wi-Fi 6 connectivity with cloud software that simplifies device management, maximizes security and minimizes expenses for enterprise users.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210209005447/en/
(C)2021. Inseego Corp. All rights reserved. Inseego Wavemaker PRO Indoor Router FG2000e
“Our Wavemaker PRO 5G solutions are changing the way enterprise and SMB customers think about broadband access,” said Inseego President Ashish Sharma. “Whether they have remote branch offices needing faster primary communications, retail locations needing failover solutions, or a distributed workforce needing dependable and secure work-from-home access to their corporate network, the FG2000e router can deliver unmatched speed, throughput and reliability — along with software solutions that make it easy for IT organizations to deploy and manage their devices, protect their networks, and reap the benefits of a multi-carrier 5G managed WAN.”
Bringing 5G enterprise solutions to global markets
The Wavemaker PRO 5G indoor router FG2000e has now received industry certifications that make it commercially available for deployments in many global markets. It’s important to understand that different countries and regions require different types of regulatory and 3GPP certifications in order to operate 5G products on mobile networks. For example, GCF certification demonstrates that products conform with 3GPP standards and will be interoperable with mobile networks worldwide. CE certification means that solutions can be sold to service providers and enterprise customers in over 30 countries of the European Economic Area (EEA) and European Free Trade Association (EFTA). RCM certification verifies that electrical and wireless equipment can be sold in Australia. And FCC certification requires a rigorous process of testing before RF products can be sold and marketed in the U.S.
Having completed all of these certifications, the FG2000e router can now be sold to service providers and enterprise customers across all of these regions, including organizations that are deploying 5G private networks.
New global channel partners
In addition to partnering with service providers, Inseego is expanding its network of distributors, resellers and system integrators worldwide to create new channels to market, along with local market support for its new enterprise solutions. The FG2000e router and software provides local language support, including English, French, Italian, Spanish, German, Arabic and Japanese.
A multi-carrier 5G cloud managed WAN for ubiquitous broadband connectivity
The Wavemaker PRO 5G indoor router FG2000e provides high-performance 5G connectivity and 4G LTE fallback, with features such as:
- Unlocked, dual-SIM, multi-carrier firmware that provides flexibility and ultimate control of the network the router connects to, avoiding downtime and data usage overage charges
- Centralized cloud management through the Inseego Manage™ cloud solution, which simplifies device configuration, installation, remote management, security and support, providing an excellent customer experience right “out of the box” and for the full product lifecycle
- Enterprise-grade security that includes WPA3 Wi-Fi security support, advanced encryption, Open VPN and IPsec VPN
- Added value with a robust pipeline of new features including WAN management, enterprise security, device management and vertical market applications.
The Wavemaker PRO 5G indoor router FG2000e can deliver gigabit-plus speeds (using sub-6 GHz 5G) that match or outperform typical cable and fiber optic speeds. The FG2000e is ideal for business offices, retail locations, medical facilities, campuses and remote job sites needing reliable, high-speed broadband access with features such as:
- A 5 Gbps ethernet port, additional LAN and WAN ports, and TS9 port for external antenna
- Wi-Fi 6 technology to support up to 128 Wi-Fi-enabled devices
- An RJ-11 port for optional Voice over LTE (VoLTE)
5G for private networks
According to IDC, the private LTE/5G equipment market will reach $5.7 Billion in 2024. “With more spectrum being made available for enterprise uses, coinciding with the arrival of commercial 5G, interest has grown toward using private LTE/5G solutions as a basis for connectivity across a multitude of mission-critical, industrial and traditional enterprise organizations.”
Inseego 5G: Fast, reliable and secure
Designed and developed in the U.S., Inseego 5G products deliver high speed and low latency with extensive cybersecurity, including WPA3 Wi-Fi security with advanced encryption, Open VPN, IPsec VPN, parental controls and more.
To learn more about Inseego 5G products and solutions go to inseego.com. For press and analyst inquires, please email press@inseego.com
* Pending carrier approval.
About Inseego Corp.
Inseego Corp. (Nasdaq: INSG) is an industry leader in smart device-to-cloud solutions that extend the 5G network edge, enabling broader 5G coverage, multi-gigabit data speeds, low latency and strong security to deliver highly reliable internet access. Our innovative mobile broadband, fixed wireless access (FWA) solutions, and software platform incorporate the most advanced technologies (including 5G, 4G LTE, Wi-Fi 6 and others) into a wide range of products that provide robust connectivity indoors, outdoors and in the harshest industrial environments.
Designed and developed in the USA, Inseego products and SaaS solutions build on the company’s patented technologies to provide the highest quality wireless connectivity for service providers, enterprises, and government entities worldwide. www.inseego.com #Putting5GtoWork
©2021 Inseego Corp. All rights reserved. The Inseego name and logo are registered trademarks, and the Wavemaker and Inseego Manage names are trademarks of Inseego Corp. Other Company, product or service names mentioned herein are the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005447/en/
Contact information
Media contact:
Anette Gaven
Tel: +1 (619) 993-3058
Email: Anette.Gaven@inseego.com
Or
Investor Relations contact:
Joo-Hun Kim, MKR Group
Tel: +1 (212) 868-6760
Email: joohunkim@mkrir.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
